The report, released July 30, analyzed pharmacy program participants’ purchase data from April 2023 to March 2024 and provides an estimate of pharmaceutical price changes for 2025.
Vizient’s analysts predicted a 4.18% drug price inflation rate for oncology medication in 2025, more than the predicted 3.81% overall drug price inflation rate.
The oncology medications that saw the biggest share of spending were:
- Keytruda (pembrolizumab): 3.28%
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 1.36%
- Opdivo (nivolumab): 1.24%
- Imfinzi (durvalumab): 0.61%
- Tecentriq (atezolizumab): 0.54%
- Blincyto (blinatumomab): 0.53%
- Jakafi (ruxolitinib phosphate): 0.50%
- Perjeta (pertuzumab): 0.48%
- Adcetris (brentuximab vedotin): 0.45%
- Tagrisso (osimertinib mesylate): 0.45%
The top oncology medications with the greatest change in spend were:
- Kisqali (ribociclib): 190% increase
- Padcev (enfortumab vedotin-efjv): 69% increase
- Blincyto (blinatumomab): 56% increase
- Imfinzi (durvalumab): 38% increase
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 17% increase
- Keytruda (pembrolizumab): 13% increase
Leave a Reply